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Background: The aims were to assess 1) the relationship of asthma control assessed by
combining epidemiological survey questions and lung function to Health-Related Quality of Life
(HRQL) and 2) whether individuals with controlled asthma reach similar generic HRQL levels as
individuals without asthma.
Methods: The analysis included 584 individuals without asthma and 498 with asthma who partic-
ipated in the follow-up of the Epidemiological study on Genetics and Environment of Asthma
(EGEA). Asthma control was assessed from survey questions and lung function, closely adapted
from the 2006e2009 Global Initiative for Asthma guidelines. The Asthma Quality of Life
Questionnaire (AQLQ, scores range:1e7) and the generic SF-36 (scores range: 0e100) were used.
Results: Adjusted mean total AQLQ score decreased by 0.5 points for each asthma control steps
(6.4, 5.9 and 5.4 for controlled, partly-controlled and uncontrolled asthma respectively,
p < 0.0001). The differences in SF-36 scores between individuals with controlled asthma and
those without asthma were minor and not significant for the PCS (1, p Z 0.09), borderline
significant for the MCS (1.6, pZ 0.05) and small for the 8 domains (<5.1) although statistically
significant for 4 domains.
Conclusion: These results support the discriminative properties of the proposed asthma control
grading system and its use in epidemiology.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Asthma control reflects the disease activity over a short
period of time and incorporates exacerbations and current
clinical control.1 Asthma control is important in clinical
practice to evaluate patients and their response to treatment
(the Global Initiative for Asthma-GINA, the National Asthma
Education and Prevention Program-NAEPP) as well as for
public health and research. Studies on asthma control have
mainly been conducted in clinical studies and few epidemi-
ologic studies in large populations of asthmatics have
addressed uncontrolled asthma assessed in a comprehensive
mannerby incorporating several dimensionsof thedisease.2,3
Poor asthma control is associated with generic and
specific health-related quality of life (HRQL) indices.4e6
Recent articles support the construct validity of the GINA
asthma control classification by studying its relationshipwith
specific control questionnaires in clinical populations.7,8 To
our knowledge, no study has attempted to examine theHRQL
impact of asthma control assessed in a comprehensive way
following the GINA guidelines by combining subjective
measures of asthma control through epidemiological survey
questions (to assess daytime and nighttime symptoms level,
rescue medication use and asthma exacerbation) and
objective measures of asthma control (lung function).
Asthma is associated with a decreased quality of life,9,10 but
it is unknown whether individuals with controlled asthma
have a decreased HRQL compared to those without asthma.
Such discriminative properties analysis, using a mixed
traditional and clinical epidemiological approach, including
healthy subjects and well characterized asthmatics,11would
provide construct validity evidence of such a grading system
of asthma control applicable in epidemiology.12
In the frame of the Epidemiological study on the
Genetics and Environment of Asthma, bronchial hyper-
responsiveness and atopy (EGEA), a French case-control
and family study on asthma with detailed information for
asthma control and quality of life for 1082 subjects, thespecific hypotheses tested in this article are that 1) asthma
control, assessed by combining data collected in that
epidemiological survey closely adapted from the GINA
guidelines, has an important impact on the quality of life
among individuals with asthma; 2) the quality of life ach-
ieved in individuals with controlled asthma is similar to the
quality of life of individuals without asthma.
Methods
Population
EGEA is a cohort study (12 years follow-up) based on an initial
group of patients with asthma recruited in chest clinics
(probands, n Z 388) and their first-degree relatives
(n Z 1244), and a group of population-based subjects
(n Z 415).13e15 Careful attention was given to address
potential biases at inclusion and during examination.15 The
population of this cross sectional analysis included 1082
individuals (250 probands, 620 relatives of probands and 212
population-based subjects) who took part in EGEA2
(2003e2007), with data available for asthma, asthma control
classification and HRQL (584 without asthma and 498 with
current asthma) (Fig. 1).3Written consentwas obtained from
all participants at both surveys. Ethical approval to carry out
the study was obtained for both surveys from the relevant
committees (Cochin Port-Royal Hospital, Paris for EGEA1 and
Necker-Enfants Malades Hospital, Paris for EGEA2).
Phenotypes
Current asthma was defined by a positive answer to one of
the two standardized questions: “Have you ever had
attacks of breathlessness at rest with wheezing?”, “Have
you ever had asthma attacks?”, and at least to one question
about asthma attack, respiratory symptoms (wheezing,
nocturnal chest tightness, attack of shortness of breath
Figure 1 Flowchart of the EGEA population.
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ment for asthma in the last 12 months.3 Individuals without
asthma were defined by negative answers to the first two
questions and report of no treatment for asthma or respi-
ratory problems in the past 12 months.
Asthma control was assessed by combining epidemio-
logical data following as much as possible the 2006e2009
GINA (Global Initiative for Asthma) guidelines.16 This clas-
sification has already been used in a previous publication
assessing the determinants of asthma control.3 Asthma was
defined as 1) controlled if all the following features,
assessed on average over the past 3 months except for
FEV1, were present: trouble with breathing less than once
a week, no asthma attacks, no nocturnal symptoms, short-
acting b2-agonists use twice or less per week in the last 3
months, no use of oral steroids in the last 12 months,
FEV1  80% of predicted value, 2) partly-controlled if 1 or 2
of the above features were absent, 3) uncontrolled if 3 of
these features were absent or if respiratory problems had
caused hospital/emergency department admissions in the
last 12 months, or if oral steroids had been used in the last
12 months or 12 asthma attacks in the past 3 months.
Quality of life questionnaires
Two standardized quality of life questionnaires were used:
1) The Asthma Quality of Life Questionnaire (AQLQ)17 an
asthma-specific instrument that consists of 32 questions,
relating to the past 2 weeks and covering four domains:
“symptoms”, “activity limitation”, “emotional func-
tion” and susceptibility to “environmental exposure”.
The minimal clinically important difference (MCID),
which is the smallest difference that has been consid-
ered as clinically and socially relevant by the devel-
opers, is 0.5.18 As previously used in the literature,19 the
HRQL score differences have been compared to the MCID
when addressing the magnitude of the differences
observed between groups, although the MCID was not
initially developed to be used in this context.
2) The SF-36 (Medical Outcomes Survey 36 item Short
Form health survey), a generic questionnaire composed
of 36 items that covers eight health status domains:
physical functioning, role limitations due to physical
problems, bodily pain, general health, vitality, social
functioning, role limitations due to emotional problems
and mental health.20 The computed scores for each
domain and the two summary component scores
(Physical Component Summary, PCS and Mental
Component Summary, MCS) range from 0 to 100, with
larger scores indicating better health status.21 There
are no recommended MCID for the summary scores, but
MCIDs for the 8 domains have been described in an
asthma population (between 10.0 and 16.7).22Statistical analyses
Mixed models that take into account the dependence of the
subjects within families were conducted with a robust esti-
mate of the standard errors (SE) because of the non-normalityof the HRQL scores. The assessment of co-morbidity is
important in HRQL research.23 Since co-morbid conditions
affect considerably less disease-specific than generic HRQL
measures,24 the analysis using the SF-36 questionnaire were
performed among individuals without co-morbidity (584
without asthma and 393 with asthma) whereas the analysis
using the AQLQ were conducted on all individuals with
asthma,with a further adjustment on co-morbidity (nZ 480).
The analysis was further conducted separately in ICS users
(ICSþ) and non-ICS users (ICS) over the past 12 months to
account for disease severity.2 All analyses were performed
using the SAS 9.1 statistical software (SAS institute, Cary, NC).
Results
Subject characteristics
The frequency of theallergy-relatedphenotypes (sensitization
to aero-allergens, high level of total IgE and rhinitis) and
bronchial hyperresponsivenessweremuchhigher in individuals
with asthma (nZ 498,mean age 39.4 years) than in individuals
without asthma (nZ 584, mean age 43.8 years) (Table 1). 93%
of individuals with asthma, reported to have ever had doctor
diagnosed asthma and half of them had used ICS in the past
12 months. In this population, 44.4%, 29.7% and 25.9% had
controlled, partly-controlled and uncontrolled asthma.
Disease-specific and generic quality of life and
asthma control
Uncontrolled asthma was associated with a significantly
decreased total AQLQ score (p < 0.0001) and partly-
controlled asthma showed intermediate total AQLQ scores
between controlled and uncontrolled asthma. A decrease by
at least 0.5 point was observed for all domains and the total
AQLQ score when comparing uncontrolled asthma to
controlled asthma, but was only observed for the symptom
score and the total AQLQ score when comparing partly-
controlled asthma to controlled asthma (Table 2). The
AQLQ scores were higher in ICS compared to ICSþ (mean
total AQLQ score were 6.4 and 5.7 respectively, p< 0.0001),
reflecting a milder disease among individuals not using ICS.
Nevertheless, the multivariate analysis stratified on ICS use
over the past 12 months showed that in both groups and for
all domains, except for Activity Limitation in ICS, uncon-
trolled asthma was related to significant decreased scores of
at least 0.5 point compared to controlled asthma (Table 2).
The physical and mental summary component scores and
all SF-36 domains were significantly decreased in uncon-
trolled asthma compared to controlled asthma (Table 3). For
three domains, Role Physical, General Health and Role
Emotional, the score differences were stronger than the
MCID thresholds defined for asthma (13.2, 12.6 and 16.7
respectively). Compared to controlled asthma, partly-
controlled asthma was associated with a significantly lower
PCS score, but no association was observed with the MCS
score (Table 3). Partly-controlled asthma showed similar SF-
36 scores to controlled asthma for all domains, except for
the General Health domain where a statistically significant
difference was observed but the difference (6.4) was lower
than theMCID previously proposed in asthma for this domain.
Table 1 Characteristics of the population.
Individuals
without
asthma and
co-morbiditya
(n Z 584)
Individuals with asthma
All
(n Z 498)
Controlled
(n Z 221)
Partly-controlled
(n Z 148)
Uncontrolled
(n Z 129)
Age, m  sd (n) 43.8  15.6 (584) 39.4  16.4 (498) c 36.8  15.5 (221) 40.6  17.0 (148) 42.4  16.6 (129)
Sex, % males (n) 46.7 (273) 50.8 (253) 53.8 (119) 54.7 (81) 41.1 (53)
Educational level
University, % (n) 51.1 (297) 49.3 (241) 49.3 (109) 53.1 (77) 44.7 (55)
Secondary, % (n) 25.5 (148) 29.0 (142) 31.2 (69) 24.1 (35) 30.9 (38)
Primary, % (n) 23.4 (136) 21.7 (106) 19.5 (43) 22.8 (33) 24.4 (30)
Current active/passive smoking
Non/ex smokers and
ETSb, % (n) 39.0 (226) 34.2 (170) 33.0 (73) 33.8 (50) 36.7 (47)
Non/ex smokers and
ETSbþ, % (n) 39.4 (228) 40.2 (200) 38.5 (85) 45.3 (67) 37.5 (48)
Current smokers, % (n) 21.6 (125) 25.6 (127) 28.5 (63) 20.9 (31) 25.8 (33)
BMI  25 kg/m2, % (n) 35.7 (199) 36.7 (178) 33.9 (75) 37.1 (53) 41.3 (50)
Co-morbidity,a % (n) e 19.3 (96) 16.7 (37) 20.3 (30) 22.5 (29)
Sensitization, % (n) 40.1 (210) 81.1 (369)c 79.5 (167) 81.5 (110) 83.6 (92)
Active rhinitis, % (n) 18.9 (109) 60.8 (298)c 56.6 (124) 60.8 (87) 68.0 (87)
Total IgE  100 IU/ml,
% (n) 29.2 (162) 61.5 (297)c 54.1 (118) 68.5 (98) 66.4 (81)
BHR, PD20  4 mg, % (n) 26.3 (103) 70.5 (198)c 66.7 (110) 74.6 (50) 77.5 (38)
Asthma
Status in the study:
Case, % (n) 50.2 (250) 37.2 (93) 30.8 (77) 32.0 (80)
Relatives or
controls, % (n) 49.8 (248) 51.6 (128) 28.6 (71) 19.8 (49)
Asthma onset:
4 years, % (n) e 31.1 (146) 31.5 (65) 30.3 (43) 31.4 (38)
[4e16], % (n) e 34.5 (162) 38.4 (79) 33.1 (47) 29.7 (36)
>16, % (n) e 34.3 (161) 30.1 (62) 36.6 (52) 38.8 (47)
ICS use in the past
12 months, % (n) e 49.4 (244) 31.0 (68) 58.2 (85) 70.5 (91)
a Non-expected co-morbidity was assessed by a positive answer to “Have you ever been treated or followed for rheumatism, Crohn
disease, poly-arthritis, heart disease, diabetes, or other serious illnesses”. For individuals who answered “other serious illnesses”, the
specific disease was reported and a medical doctor decided whether the condition(s) declared could be considered as a co-morbid
condition in the context of this study of HRQL.
b ETS : Environmental Tobacco Smoke.
c p < 0.001 for the difference between individuals without asthma those with asthma.
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controlled asthma vs. individuals without asthma
Mean SF-36 physical and mental summary scores were lower
in thewhole group of individuals with asthma as compared to
individuals without asthma (adjusted means (SE) in individ-
ualswith asthmaand individualswithout asthmawere for the
PCS score 51.8 (0.45) vs. 54.1 (0.31), p < 0.0001 and for the
MCS score 46.5 (0.65) vs. 49.2 (0.56), pZ 0.0007).
Individuals with controlled asthma had similar PCS
scores and lower MCS scores when compared to those
without asthma (Table 3). Similar results were observed
even in subjects with controlled asthma who had used ICS in
the past year (nZ 54) (adjusted mean (SE) PCS scores were
53.9 (0.8) and 54.3 (0.4) and adjusted mean (SE) MCS score
were 47.7 (1.4) and 49.2 (0.6) for controlled asthma andnon asthma respectively). Regarding each SF-36 domain,
individuals with controlled asthma showed statistically
significantly lower scores for Physical Functioning, General
Health, Social Functioning and Mental Health compared to
individuals without asthma. However none of the observed
differences reached 5 when the MCIDs defined in asthma for
these domains are 10 or greater, indicating that although
being statistically significant, the magnitudes of the
differences were relatively small.Discussion
Uncontrolled asthma, assessed by combining epidemiolog-
ical data on day and night symptoms, use of reliever
therapy, lung function and exacerbation was significantly
Table 2 Disease-specific quality of life (AQLQ) according to asthma control.
Adjusteda mean (SE) AQLQ scores
Activity limitation Symptoms Emotional function Environmental exposure AQLQ total
Among all individuals with asthma (n Z 429)
Controlled asthma (ref.) 6.3 (0.06) 6.3 (0.07) 6.5 (0.08) 6.4 (0.09) 6.4 (0.06)
Partly-controlled asthma 6.0 (0.09)d 5.7 (0.10)d 6.1 (0.12)d 6.0 (0.11)d 5.9 (0.08)d
Uncontrolled asthma 5.7 (0.11)d 5.1 (0.12)d 5.7 (0.13)d 5.6 (0.12)d 5.4 (0.10)d
Among individuals with asthma who used ICS in the past 12 months (n Z 213)
Controlled asthma (ref.) 6.3 (0.12) 6.1 (0.12) 6.4 (0.14) 6.2 (0.16) 6.2 (0.11)
Partly-controlled asthma 6.0 (0.12)b 5.7 (0.13)b 6.1 (0.15) 6.0 (0.14) 5.9 (0.11)b
Uncontrolled asthma 5.5 (0.14)d 4.9 (0.15)d 5.5 (0.16)d 5.5 (0.15)c 5.3 (0.13)d
Among individuals with asthma who did not used ICS in the past 12 months (n Z 212)
Controlled asthma (ref.) 6.4 (0.08) 6.4 (0.08) 6.7 (0.08) 6.5 (0.12) 6.5 (0.07)
Partly-controlled asthma 6.3 (0.12) 5.8 (0.13)d 6.2 (0.15)d 6.1 (0.18)b 6.1 (0.11)d
Uncontrolled asthma 6.1 (0.13)b 5.7 (0.17)d 6.2 (0.17)c 5.8 (0.22)c 5.9 (0.13)d
a Models were adjusted by age, sex, educational level, smoking, BMI, sensitization, allergic rhinitis, IgE, co-morbidity and centre.
b p < 0.05.
c p < 0.01.
d p < 0.001 in comparison with the reference group (controlled asthma) and estimated with mixed model with a robust estimate of the
standard errors.
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compared to controlled asthmatics that exceeded the
MCID. This study, by comparing HRQL between subjects
with controlled asthma and healthy subjects, suggests that
the health status impairment is minimal if asthma control is
achieved.
The strength of the present analysis lies on the large and
well characterized population of adults with asthma and
without asthma recruited in the framework of the EGEA
study. In the present analysis, a sensitive current asthma
phenotype, supported by the high frequencies of the
allergic phenotypes and of BHR among the individuals with
asthma, and a specific definition of individuals without
asthma were used. Another strength of the present analysis
is the use of both a standardized generic questionnaire (SF-
36) and an asthma-specific questionnaire (AQLQ). Data
available in the EGEA2 study made it possible to take into
account a large number of confounders.3 The comprehen-
sive asthma control classification used allows accounting
for multiple features of asthma control by combining both
objective and subjective measures of asthma control. The
inclusion of lung function in the asthma control assessment
is supported by a previous factorial analysis showing that
asthma health status is composed of distinct components,
lung function being one of them,25 and by clustering anal-
ysis showing that an impaired lung function is observed for
specific asthma phenotypes.26 However, a limitation of this
classification lies on the lack of data on activity limitation,
one dimension of asthma control integrated in the GINA
guidelines. Nevertheless, the lack of this dimension is
expected to impair asthma control classification in only few
subjects, as suggested by unpublished data in ECRHSII
showing that among 1032 patients with current asthma the
activity limitation had an impact on the asthma control
level in only 8.7% subjects. Compared to the time period
used in some asthma control questionnaires or following the
current clinical guidelines (one to four weeks), a longer
time period was used in the EGEA study (3 months), which
most likely results in decreasing the strength of theassociation with HRQL, as HRQL questionnaire relates to
a much shorter time (2 weeks for the AQLQ and 4 weeks for
the SF-36 questionnaire). However, there is no reason to
expect a differential or systematic bias that would lead to
underestimate or overestimate the association. The lack of
asthma control in this population is due either to under-
treatment (supported by the observation that 42% and
30% of the individuals with partly-controlled and uncon-
trolled asthma respectively did not use ICS in the past year)
or to the lack of response to asthma treatment (supported
by the observation that half of the subjects with uncon-
trolled asthma used high daily treatment level, GINA step 3
and 4, in the past 3 months) as previously reported.3
Present findings show that uncontrolled asthma was
significantly associated with decreased AQLQ scores, which
confirm previous studies using standardized asthma control
tools.4,5 Individuals with partly-controlled asthma had
intermediate AQLQ scores between those with controlled
and uncontrolled asthma. Our results, showing a greater
impact of partly-controlled asthma on the symptoms
domain compared to the emotional function and environ-
mental exposure domains are in agreement with previous
studies.19,27 The lack of difference between partly-
controlled asthma and controlled asthma using the SF-36
questionnaire, may be explained by a lower sensitivity of
generic questionnaires to detect small differences in
HRQL.28
Clinical and epidemiological studies have shown
a decreased HRQL in more severe asthma.29e31 The similar
pattern of association between asthma control and AQLQ
score observed among subjects using ICS treatment and
those not using ICS treatment suggest that the proposed
asthma control classification is able to discriminate levels
of HRQL in both individuals with mild and more severe
asthma.
As expected and previously shown in other populations,
individuals with asthma as a group had an impaired quality
of life compared to individuals without asthma.9,10 More-
over, our results indicate that HRQL in individuals with
Table 3 Generic quality of life (SF-36) according to asthma and asthma control.
Adjusteda mean (SE) SF-36 physical component scores Adjusteda mean (SE) SF-36 mental component scores
Physical
functioning
Role
physical
Bodily pain General
health
PCS Vitality Social
functioning
Role
emotional
Mental
health
MCS
No asthma 93.1 (0.7) 91.3 (1.4) 78.3 (1.2) 75.3 (0.9) 54.1 (0.4) 60.3 (1.0) 84.8 (1.2) 84.5 (1.7) 68.9 (0.9) 49.0 (0.5)
Controlled asthma 89.4 (1.1) 88.3 (2.0) 78.9 (1.7) 70.2 (1.3) 53.1 (0.5) 58.0 (1.3) 79.7 (1.6) 80.5 (2.4) 65.5 (1.5) 47.4 (0.9)
Partly-controlled asthma 87.6 (1.3) 88.6 (2.5) 78.6 (2.3) 63.8 (1.9) 51.7 (0.7) 56.9 (1.6) 77.9 (2.0) 83.3 (3.1) 65.9 (1.6) 47.8 (0.9)
Uncontrolled asthma 82.8 (1.7) 75.1 (3.6) 70.6 (2.4) 57.6 (1.9) 49.2 (0.9) 51.7 (2.0) 68.8 (2.6) 63.8 (4.3) 60.2 (2.1) 43.1 (1.4)
Statistical test for the comparison of HRQL scores between controlled asthma and no asthma
Controlled asthma vs. no asthma,
Scores difference 3.7 3.0 0.6 5.1 1 2.3 5.1 4.0 3.4 1.6
p value 0.002 0.19 0.79 0.0004 0.09 0.14 0.005 0.14 0.03 0.05
Statistical test for the comparison of HRQL scores between asthma control steps
Partly-controlled vs. controlled asthma
Scores difference 1.8 0.3 0.3 6.4 1.4 1.1 1.8 2.8 0.4 0.4
p value 0.25 0.90 0.91 0.002 0.05 0.55 0.42 0.43 0.82 0.74
Uncontrolled vs. partly-controlled asthma
Scores difference 4.8 13.5 8.0 6.2 2.5 5.2 9.1 19.5 5.7 4.7
p value 0.02 0.001 0.01 0.02 0.02 0.03 0.004 0.0002 0.03 0.005
Uncontrolled vs. controlled asthma
Scores difference 6.6 13.2 8.3 12.6 3.9 6.3 10.9 16.7 5.3 4.3
p value 0.0006 0.0006 0.004 <0.0001 <0.0001 0.008 0.0002 0.0006 0.03 0.008
Adjusted means were estimated with mixed model with a robust estimate of the standard errors.
a Models were adjusted by age, sex, educational level, smoking, BMI, sensitization, allergic rhinitis, IgE and centre.
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Asthma control and health-related quality of life 827controlled asthma is comparable to HRQL in individuals
without asthma. The lack of association between the SF-36
PCS score and controlled asthma is not due to a lack of
statistical power as the power of 80% was reached for
differences between control asthma and no asthma greater
than 1.3; this represents a really reasonable difference
compared with previous published articles in population-
based study showing PCS decreased by 5 points with
asthma.10 The lack of difference between SF-36 component
summary scores and controlled asthma was observed for
the group of individuals with asthma who had used ICS in
the past year and it may be an important message for
encouraging the achievement of optimal control in pop-
ulations. It is unlikely that potential misclassification could
explain this result since asthma characterization was good.
Although no major differences between individuals with
asthma and those without asthma was observed on several
personal and socio-economic characteristics (sex, smoking,
educational level and BMI), selection bias may have
occurred on other factors and a replication of our results in
a larger population-based study is warranted.Conclusion
The proposed approach to assess asthma control in epide-
miology, using a comprehensive manner adapted from the
GINA guidelines, is strongly associated with HRQL.
Furthermore, although some of the SF-36 domain scores
differences were statistically different between individuals
with controlled asthma and those without asthma, the
differences observed were of small magnitude, indicating
that the health status impairment is minimal if asthma
control is achieved. These results support the discrimina-
tive properties of such an asthma control grading system
applicable in epidemiological studies. Its use in epidemi-
ology could provide useful tools to identify risk factors for
uncontrolled asthma and to compare the quality of asthma
management between different populations.Acknowledgments
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